Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small Cell Lung (NSCLC), as well as various lymphomas and leukemias; melanoma, endometrial, gastric, breast, colorectal, and pancreatic cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Chromatin Pionee | Foghorn Therapeutics leads in developing novel oncology therapies targeting the chromatin regulatory system, with potential to revolutionize cancer treatment |
FHD-909 Breakthrough | Explore the promise of FHD-909, a selective SMARCA2 inhibitor showing compelling preclinical results for NSCLC with SMARCA4 mutations |
Strategic Alliances | Learn about Foghorn's $300 million partnership with Eli Lilly, validating its Gene Traffic Control platform and boosting financial support |
Market Potential | Analysts estimate peak SMARCA2 sales could reach $1.2 billion worldwide, with price targets ranging from $9 to $13 per share |
Metrics to compare | FHTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFHTXPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.8x | −0.5x | −0.5x | |
PEG Ratio | −0.10 | −0.02 | 0.00 | |
Price/Book | −3.7x | 2.4x | 2.6x | |
Price / LTM Sales | 11.8x | 8.1x | 3.3x | |
Upside (Analyst Target) | 127.3% | 309.8% | 38.9% | |
Fair Value Upside | Unlock | 16.3% | 5.4% | Unlock |